ReNeuron Group PLC (LON:RENE) said positive long-term data on its CTX cell therapy for stroke was presented at the American Heart Association International Stroke Conference in Los Angeles on Thursday.
Professor Keith Muir, of the Queen Elizabeth University Hospital, Glasgow, and Principal Investigator for ReNeuron’s PISCES II study, told the audience that upper limb functional recovery was “durable and maintained” out to 12 months post-treatment.
A total of 30% of patients responded when assessed using the ARAT scale, a measure of upper limb mobility.
Data was also presented showing a response rate in 30% of people at 12 months post-treatment of at least a one point improvement on the modified Rankin Scale. This is a seven-point global measure of disability or dependence upon others in carrying out activities of daily living.
A one-point improvement is proven to be clinically meaningful for patients, both in terms of quality of life and healthcare resources needed to care for them.
Analysis of a subgroup of patients who had residual upper limb movement showed an “appreciably higher response rate” of 43% when measured using the modified Rankin scale.
ReNeuron shares were down 0.5% to 136.8p in late afternoon trading on Friday.
--Updates for share price and video link--